VKTX241227P100000
- 0.00
- 0.000.00%
Viking Therapeutics Newsroom
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)
Will Viking Therapeutics, Inc. (VKTX) Make You Rich In 2025?
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
Stocks on Sale: Novo Nordisk, Viking Therapeutics, Nike, and Bitcoin
Insider Sellers Might Regret Selling Viking Therapeutics Shares at a Lower Price Than Current Market Value
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark
Why Viking Therapeutics Tumbled by More Than 10% This Week
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know
Stocks to Watch Friday: Trump Media, Novo Nordisk, Eli Lilly, Tesla -- WSJ
B.Riley Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $109
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
B.Riley Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Looking Into Viking Therapeutics's Recent Short Interest
Why Is Novo Nordisk Crashing After Data for Next-gen Weight Loss Drug?
BTIG Reiterates Buy on Viking Therapeutics After Novo's CagriSema 'Underwhelms'
Amgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations
Viking Therapeutics Stock Surges 12% Amid Novo Nordisk Trial Woes
Express News | Shares of Viking Therapeutics up 9.3%, Structure Therapeutics up 3.4%, Altimmune up 1.7% Premarket
Express News | Weight Loss Drug Developers Rise Intraday Trading After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected
Hims & Hers Shares Tumble as FDA Resolves Obesity Drug Shortage